Back to Search Start Over

Tight junction proteins in gastrointestinal and liver disease

Authors :
Punita Dhawan
Mirjam B. Zeisel
Thomas F. Baumert
Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL)
Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL)
Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Interactions Virus-Hôte et Maladies Hépatiques
Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Virologie
Université de Strasbourg (UNISTRA)
Department of Biochemistry and Molecular Biology
University of Nebraska Medical Center
University of Nebraska System-University of Nebraska System
Buffet Cancer Center [Omaha, NE, USA]
VA Nebraska-Western Iowa Health Care System [Omaha, NE, USA]
Pôle hépato-digestif [Strasbourg]
Nouvel Hôpital Civil, Hospices Civils de Strasbourg-Institut Hospitalo-Universitaire de strasbourg
ARC, Paris and Institut Hospitalo-Universitaire, Strasbourg (TheraHCC IHUARC IHU201301187), the European Union (ERC-AdG-HEPCIR, ERC-PoC-2016-PRELICAN, EU H2020-667273-HEPCAR, U Strasbourg Foundation HEPKIN), the National Institutes of Health (NCI 1R21CA209940-01A1, NIAID R03AI131066, NIAID 5U19AI123862-02), the Institut Universitaire de France (IUF), the IdEx Program of the University of Strasbourg, the Impulsion Program of the IDEXLYON, BX002086 (VA merit), CA216746 (NIH/NCI) and a pilot project award from Fred and Pamela Buffet Cancer Center, which is funded by a National Cancer Institute Cancer Center Support Grant under award number P30 CA036727. This work has been published under the framework of the LABEX ANR-10-LABX-0028_HEPSYS and benefits from funding from the state managed by the French National Research Agency as part of the investments for the future programme.
ANR-10-LABX-0028,HepSys,Functional genomics of viral hepatitis and liver disease(2010)
European Project: 667273,H2020,H2020-PHC-2015-two-stage,HEP-CAR(2016)
European Project: 671231,H2020,ERC-2014-ADG,HEPCIR(2016)
European Project: 755460,PRELICAN
Zeisel, Mirjam
Mechanisms underlying hepatocellular carcinoma pathogenesis and impact of co-morbidities. - HEP-CAR - - H20202016-01-01 - 2019-12-31 - 667273 - VALID
Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Source :
Gut, Gut, 2018, Epub ahead of print. ⟨10.1136/gutjnl-2018-316906⟩, Gut, In press, Epub ahead of print. ⟨10.1136/gutjnl-2018-316906⟩, Gut, BMJ Publishing Group, In press, Epub ahead of print. ⟨10.1136/gutjnl-2018-316906⟩
Publication Year :
2018
Publisher :
BMJ, 2018.

Abstract

Over the past two decades a growing body of evidence has demonstrated an important role of tight junction (TJ) proteins in the physiology and disease biology of gastrointestinal (GI) and liver disease. On one side, TJ proteins exert their functional role as integral proteins of TJs in forming barriers in the gut and the liver. Furthermore, TJ proteins can also be expressed outside TJs where they play important functional roles in signaling, trafficking and regulation of gene expression. A hallmark of TJ proteins in disease biology is their functional role in epithelial-to-mesenchymal transition. A causative role of TJ proteins has been established in the pathogenesis of colorectal cancer and gastric cancer. Among the best characterized roles of TJ proteins in liver disease biology is their function as cell entry receptors for hepatitis C virus – one of the most common causes of hepatocellular carcinoma. At the same time TJ proteins are emerging as targets for novel therapeutic approaches for GI and liver disease. Here we review our current knowledge of the role of TJ proteins in the pathogenesis of GI and liver disease biology and discuss their potential as therapeutic targets.

Details

ISSN :
14683288 and 00175749
Volume :
68
Database :
OpenAIRE
Journal :
Gut
Accession number :
edsair.doi.dedup.....dc08a574791f230555a867f5c6921e13